J
James C. Yao
Researcher at University of Texas at Austin
Publications - 15
Citations - 1709
James C. Yao is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Octreotide & Neuroendocrine tumors. The author has an hindex of 10, co-authored 15 publications receiving 1527 citations. Previous affiliations of James C. Yao include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
James C. Yao,Alexandria T. Phan,Paulo M. Hoff,Helen X. Chen,Chusilp Charnsangavej,Sai Ching J. Yeung,Kenneth R. Hess,Chaan Ng,James L. Abbruzzese,Jaffer A. Ajani +9 more
TL;DR: Bvacizumab therapy resulted in objective responses, reduction of tumor blood flow, and longer PFS in patients with carcinoid than PEG interferon treatment.
Journal ArticleDOI
Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Matthew H. Kulke,Lillian L. Siu,Joel E. Tepper,George A. Fisher,D. E. Jaffe,Daniel G. Haller,Lee M. Ellis,Jacqueline Benedetti,Emily K. Bergsland,Timothy J. Hobday,Eric Van Cutsem,James F. Pingpank,Kjell Öberg,Steven J. Cohen,Mitchell C. Posner,James C. Yao +15 more
TL;DR: Key recommendations include the evaluation of pancreatic NET separately from NETs of other sites and the exclusion of patients with poorly differentiated histologies from trials focused on low-grade histologies.
Journal ArticleDOI
Gastroenteropancreatic high-grade neuroendocrine carcinoma.
TL;DR: Platinum‐based chemotherapy may not be the optimal treatment for patients who have GEP‐NEC with a moderately high proliferation rate, and patients with such tumors or with well differentiated morphology had better survival than patients who had tumors with poorly differentiated morphology or a higher Ki‐67 index.
Journal ArticleDOI
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
James C. Yao,Marianne Pavel,Catherine Lombard-Bohas,Eric Van Cutsem,Maurizio Voi,Ulrike Brandt,Wei He,David Chen,Jaume Capdevila,Elisabeth G.E. de Vries,Paola Tomassetti,Timothy J. Hobday,Rodney F. Pommier,Kjell Öberg +13 more
TL;DR: Everolimus was associated with a median OS of 44 months in patients with advanced, progressive pancreatic NET, the longest OS reported in a phase III study for this population, although this finding was not statistically significant.
Journal ArticleDOI
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
TL;DR: Rapamycin causes significant growth inhibition in carcinoid tumor cell lines in vitro and in vivo, thus mTOR is a promising therapeutic target for neuroendocrine tumors and octreotide does not enhance the efficacy of rapamycin's antiproliferative effects in the models tested.